The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders

Skåne University Hospital0 个研究点开始时间: 2017年1月30日最近更新: 2017年5月22日

试验速览

暂无简介。

•Healthy elderly subjects
•- No cognitive symptoms reported by study participant
•- Normal performance on cognitive tests
•- General cognition and functional performance preserved such that a
•diagnosis of MCI or dementia cannot be made by physician at the time of the baseline visit
•- Between 20 and 100 years of age
•- Fluent in Swedish
•- Agrees to at least one lumbar puncture, MRI scan of the brain and neuropsychological testing.
•Mild cognitive impairment/dementia
•- Cognitive symptoms reported by patient and/or informant
•- Between 20 and 100 years of age
•- General cognition and functional performance sufficiently preserved such that a diagnosis of dementia cannot be made by physician at the time of the baseline visit (MCI)
•- General cognition and functional performance fulfilling a diagnosis of dementia at the time of the baseline visit (Dementia group)
•- Fluent in Swedish
•- Agrees to at least one lumbar puncture, MRI scan of the brain and neuropsychological testing.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 400
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 900

•Exclusion Criteria:
•- Major depression as described in DSM-IV.
•- History of schizophrenia or other recurrent psychotic disorder
•- History of alcohol or substance abuse or dependence within the past 5 years
•- Diseases that will make study participation difficult, such as terminal cancer or significant heart failure.
•- Certain neurologic diseases, such as Huntington's disease, normal pressure hydrocephalus, brain tumor, subdural hematoma, multiple sclerosis, or persistent neurologic deficits or known structural brain abnormalities.

发起方

Skåne University Hospital